WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...

Wave Life Sciences (WVE) announced clinical trial application, CTA, approval and initiation of the Phase 1 INLIGHT clinical trial of WVE-007 in ...

A research team from POSTECH has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

A research team has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

A research team led by Professor Won Jong Kim from the Department of Chemistry at POSTECH, in collaboration with the Korea ...

CAMBRIDGE, Mass. - Wave Life Sciences Ltd . (NASDAQ:WVE), a clinical-stage biotechnology company with a market capitalization of $1.87 billion, has announced the commencement of its Phase 1 INLIGHT ...

US-based immuno-dermatology company Alys Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA ...

The company has already kicked off an open-label Phase I trial of ABX1100 in Canada following positive results from a study of healthy volunteers.

As 2025 kicks off there’s lots of activity in the world of IP – particularly in the Biotech and Pharma sectors, writes Marc ...

Power outages can often last for days or longer and cause major disruptions in lighting, heating, refrigeration, and more.

The Oregon Center for Creative Learning and the Black Alliance and Social Empowerment, or BASE, are hosting a Black History ...